Barr Pharmaceuticals is lobbying for a US law that would allow the sale of copied medicines made by the biotech industry. Barr is dispatching almost a dozen representatives along with many other generic drug lobbyists, to try to pass their law. Other biotech companies such as Amgen and Genetech Inc. stand firmly in opposition of the new law. They contest that making copies of the highly complex gene based medication pose a higher health risk than copying the tradition treatments. According to a report on Bloomberg.com, “the outcome of the fight will determine whether generic makers, including Barr and Israel-based Teva Pharmaceutical Industries Ltd., can sell competing versions of biotech medications when they lose patent protection. Generic biotech drugs may reduc View the rest of this article
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment